Live feed06:00:00·6mPRReleasevia QuantisnowIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung CancersByQuantisnow·Wall Street's wire, on your screen.IDYA· IDEAYA Biosciences Inc.Health Care
